Drug Discovery World

JUNE 6, 2024

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. months after initial treatment. The follow-up of the Phase IIb study took place 34.9 It showed that the 2.5-year compared to 55.6%

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

AUGUST 15, 2023

Viruses have different proteins on their surfaces that are often the targets of therapeutics like monoclonal antibodies and vaccines. But targeting these proteins has limitations, as viruses can quickly evolve, changing the properties of the proteins and making treatments less effective.

Virus 130

Virus Vaccine Treatment Research 130

Drug Discovery World

JANUARY 12, 2024

A study has revealed that Covid-19 vaccines are effective in preventing long Covid, but the BioNTech/Pfizer vaccine provided better protection than ChAdOx1, developed by Oxford University/AstraZeneca. We encourage continued efforts to understand and approach treatments for long Covid.”

Vaccine 147

Vaccine Virus Treatment Research 147

Drug Discovery World

AUGUST 7, 2023

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘ Disease X ‘, a term used because what might trigger the next pandemic is unknown.

Vaccine 130

Vaccine Virus Clinical Trials Disease 130

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drug Discovery World

MARCH 17, 2023

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. However, to date, there have been severely limited treatment options for those affected.

Virus 130

Virus Regulations Licensing Licensing 130

Drug Discovery World

SEPTEMBER 26, 2024

Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. A new eBook, sponsored by Sino Biological, examines the latest innovations that are driving the market and overcoming the challenges associated with these treatments.

Virus 130

Virus Therapies Vaccine Treatment 130

Drug Discovery World

OCTOBER 31, 2022

A new study in the US has revealed that the Covid-19 vaccine is less effective in people with weakened immune systems. . The research from the Centers for Disease Control and Prevention’s VISION Network analysed real-world data on mRNA vaccine effectiveness during Omicron BA.4 5 predominance for immunocompromised adults. .

Vaccine 130

Vaccine Virus Hospitals Treatment 130

Drug Discovery World

DECEMBER 22, 2022

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. . The post AI identifies drug candidates for respiratory syncytial virus appeared first on Drug Discovery World (DDW).

Virus 130

Virus Clinical Trials Drugs Hospitals 130

Drug Discovery World

JULY 14, 2022

Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox. . The therapy has also been approved for the treatment of complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. .

Treatment 130

Treatment Pharmaceutical Companies Vaccine Virus 130

Drug Discovery World

OCTOBER 24, 2022

A scientist at Oregon State University has demonstrated in a mouse model that it’s possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2 virus from entering cells and causing respiratory disease. . This prevents the virus from latching onto cells in the host’s airway. .

Treatment 100

Treatment RNA Protein Production Virus 100

Drug Discovery World

JULY 12, 2024

Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease. for disease-modifying Parkinson’s treatment Mission Therapeutics has been awarded $5.2

Clinical Trials 130

Clinical Trials Virus Trials Vaccine 130

Drug Discovery World

SEPTEMBER 23, 2024

Insights into this signalling pathway provide a foundation for new approaches to the treatment of cancer and autoimmune diseases as well as vaccine development,” said Daniel Podolsky, President of UT Southwestern. Dr Chen’s discoveries include MAVS, the first mitochondrial protein known to be involved in immunity against infections.

Molecular Biology 147

Molecular Biology Immune Response DNA Virus 147

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus. Official comments .

Clinical Trials 130

Clinical Trials Trials Virus Vaccine 130

Drug Discovery World

AUGUST 7, 2024

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. It is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection.

Drug Trials 147

Drug Trials FDA Trials Immune Response 147

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases. News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

Drug Discovery World

MAY 24, 2024

Could a modified cold sore virus cure brain cancer? A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The post This week in drug discovery (20-24 May) appeared first on Drug Discovery World (DDW).

Virus 130

Virus Drugs Vaccine Disease 130

Drug Discovery World

JANUARY 17, 2024

The study examined viral evolution in eight Omicron variants to better understand how the virus has reacted since the introduction of vaccinations. Since the beginning of the Covid-19 pandemic, new variants of concern emerged independently from the first wave SARS-CoV-2 virus. Treatments are available. The success of BA.1

Virus 130

Virus Vaccine Immune Response Research 130

The Pharma Data

APRIL 27, 2023

This is the first time an RSV vaccine candidate for adults has gained a positive opinion, one of the final steps in the marketing authorisation procedure prior to approval by the European Commission. There are no RSV vaccines or specific treatments currently available for older adults. Efficacy was 94.6% (95% CI, 65.9–99.9,

Virus 40

Virus Vaccine Trials Clinical Trials 40

The Pharma Data

SEPTEMBER 23, 2020

Scientists around the globe are working on potential vaccines for coronavirus. The UK could be the first country in the world to carry out Covid “challenge trials” – where healthy volunteers are deliberately infected with coronavirus to test possible vaccines. How close are we to a coronavirus vaccine?

Virus 52

Virus Vaccine Government Trials 52

Codon

AUGUST 26, 2024

He also explains how they could be used to combat pandemics on “day zero,” well before vaccines are developed. After the outbreak ended, it took another three years for the first Ebola vaccine by Merck to be approved. Timelines for vaccine development are shrinking, but can it move even faster?

RNA 87

RNA Virus DNA Vaccine 87

Drug Discovery World

AUGUST 24, 2022

A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments. . The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment.

Research 246

Research Clinical Trials Virus Trials 246

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Discovery World

NOVEMBER 4, 2022

Meanwhile, the quest to understand Covid-19 continues, as study findings reveal how the virus affects the brain and the effectiveness of vaccines in those with compromised immunity. . Covid-19 vaccine less effective in the immunocompromised . The top stories: . Green light for potential AAV gene therapy .

Vaccine 130

Vaccine Drugs Therapies Virus 130

Drug Discovery World

FEBRUARY 24, 2023

Our news highlights this week focus on research into vaccines, with good news for the treatment or prevention of various challenging conditions, including Covid-19, Strep A and HIV. Particularly interesting is the announcement that a new class of Covid-19 booster has outperformed approved vaccines in a head-to-head trial.

Vaccine 130

Vaccine Drugs Clinical Trials Virus 130

Drug Discovery World

JANUARY 16, 2024

The company says that all authorised SARS-CoV-2 therapeutic antibodies that have been used in the clinic show severe to complete loss of virus neutralisation potency against the currently circulating variants. XVR013m and XVR014 neutralise both SARS-CoV-1 and SARS-CoV-2 viruses. XVR012 demonstrates an IC50 range of 0.8

Virus 262

Virus Vaccine Disease Drugs 262

Drug Discovery World

JUNE 7, 2023

Compared with traditional mRNA vaccine delivery platforms, the RALA platform has the added advantage of ease of scalability and logistics, including stability at room temperature. pHion’s pipeline also includes differentiated therapeutic vaccines for the treatment of ovarian (PTX_V5) and prostate (PTX_V3) cancers.

Vaccine 130

Vaccine Testimonials Clinical Trials Laboratories 130

Drug Discovery World

JUNE 7, 2023

The genus comprises six different established species including Hendra virus and Nipah virus, from which it receives its name. Currently there are no approved drugs or vaccines for neither Hendra nor Nipah virus infections available, underlining an urgent need for accelerated research and development.

RNA 130

RNA Small Molecule Virus Vaccine 130

Drug Discovery World

FEBRUARY 24, 2023

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial. The trial also evaluated the efficacy of HTI vaccines in combination with VES to avoid, delay or contain viral rebound compared to a placebo group.

Immune Response 130

Immune Response Vaccine Trials Clinical Trials 130

Drug Discovery World

JUNE 9, 2023

UQ Vice-Chancellor Professor Deborah Terry said the Brisbane-Atlanta partnership will bring together world-class researchers to accelerate the development of vaccines to help deliver commercial and public health outcomes. The post Brisbane-Atlanta partnership focuses on pandemic response appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Clinical Trials Virus Government 130

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 130

Research Vaccine Government Clinical Trials 130

Drug Discovery World

JULY 24, 2023

The following novel medicines and biosimilars each received a positive opinion: Abrysvo (bivalent, recombinant) , a vaccine to protect small infants and older people against lower respiratory tract disease caused by respiratory syncytial virus (RSV). Inaqovi (decitabine/cedazuridine) for the treatment of acute myeloid leukaemia.

Biosimilars 130

Biosimilars Virus Treatment Marketing 130

Drug Discovery World

JANUARY 22, 2024

In 2023, SandboxAQ announced a bio-pharma molecular simulation division, AQBioSim, to help biopharma and research institutions make treatment breakthroughs for patients. The company’s technology includes crypto-agile security, quantum sensing, and quantum simulation and optimisation.

Vaccine 147

Vaccine Immune Response Engineering Virus 147

Drug Discovery World

SEPTEMBER 26, 2023

Researchers have uncovered a link between antiviral drug molnupiravir and a pattern of mutations in the SARS-CoV-2 virus. Molnupiravir induces mutations in the virus’s genome during replication, with the aim of damaging or killing the virus.

Virus 130

Virus Clinical Trials Treatment Research 130

Drug Discovery World

JULY 22, 2022

Covid-19 vaccines remain effective six months after second dose . Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.? . An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection.? .

DNA 130

DNA Clinical Trials Vaccine Virus 130

Drug Discovery World

JUNE 16, 2023

GSK faces RSV vaccine threat from rival Pfizer An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market.

FDA Approval 130

FDA Approval Clinical Trials FDA Drugs 130

Eye on FDA

DECEMBER 15, 2021

We are long gone from the days of being threatened by a rampant Alpha virus to having several successive variants. We now have multiple vaccines – mRNA and traditional in the U.S. We now have multiple vaccines – mRNA and traditional in the U.S. What is fully vaccinated today may not be fully vaccinated tomorrow.

Vaccine 72

Vaccine Nurses Virus Treatment 72